Latest Content

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care.

A woman shares how vision loss led to her cancer diagnosis and how lifestyle changes, support and community helped her regain control after her cancer had spread.

Cindy and Katie share how caring for parents with cholangiocarcinoma led to friendship, support and advocacy through the Cholangiocarcinoma Foundation.

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.

As a breast cancer survivor, I try to stay up to date on new ways to detect cancer early. When I first heard about a simple blood test called Cancerguard, I sat up a little straighter.

The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.

For Maureen Green, scalp cooling was a crucial part of her breast cancer treatment journey, as it prevented chemotherapy-induced hair loss.

A survivor shares how hearing loss and cancer deepened her grief, leading her to confront denial and embrace support from her church community.

Ten years after first being diagnosed with breast cancer, Cynthia Malaran said she still faces some side effects from treatment, but she has found strategies for coping.

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.